The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up

Ravin J. Garg, Hagop Kantarjian, Susan O'Brien, Alfonso Quintás-Cardama, Stefan Faderl, Zeev Estrov, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP), and 13 in blast phase (BP). Best response to third TKI in CP was 5 major molecular responses (MMR), 3 complete cytogenetic (CCyR), 2 partial cytogenetic (PCyR), 3 minor cytogenetic (mCyR), 6 complete hematologic responses (CHR), and 6 with no response (NR). In AP, 1 patient achieved MMR, 1 CCyR, 2 PCyR, 1 mCyR, 4 CHR, and 1 NR. In BP, 1 achieved MMR, 2 CCyR, 1 PCyR, 1 mCyR, 2 returned to CP, and 6 NR. Median CCyR duration was 16.3 months; 3 CP patients achieving CCyR had a response more than 12 months. Median failure-free survival was 20 months for patients in CP, 5 months in AP, and 3 months in BP. Use of second-generation TKI after failure to 2 TKIs may induce responses, but these are usually not durable except in some CP patients. New treatment options are needed.

Original languageEnglish (US)
Pages (from-to)4361-4368
Number of pages8
JournalBlood
Volume114
Issue number20
DOIs
StatePublished - Nov 12 2009

Fingerprint

TYK2 Kinase
Protein-Tyrosine Kinases
Blast Crisis
Cytogenetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Garg, R. J., Kantarjian, H., O'Brien, S., Quintás-Cardama, A., Faderl, S., Estrov, Z., & Cortes, J. (2009). The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Blood, 114(20), 4361-4368. https://doi.org/10.1182/blood-2009-05-221531

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors : Long-term follow-up. / Garg, Ravin J.; Kantarjian, Hagop; O'Brien, Susan; Quintás-Cardama, Alfonso; Faderl, Stefan; Estrov, Zeev; Cortes, Jorge.

In: Blood, Vol. 114, No. 20, 12.11.2009, p. 4361-4368.

Research output: Contribution to journalArticle

Garg, RJ, Kantarjian, H, O'Brien, S, Quintás-Cardama, A, Faderl, S, Estrov, Z & Cortes, J 2009, 'The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up', Blood, vol. 114, no. 20, pp. 4361-4368. https://doi.org/10.1182/blood-2009-05-221531
Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Blood. 2009 Nov 12;114(20):4361-4368. https://doi.org/10.1182/blood-2009-05-221531
Garg, Ravin J. ; Kantarjian, Hagop ; O'Brien, Susan ; Quintás-Cardama, Alfonso ; Faderl, Stefan ; Estrov, Zeev ; Cortes, Jorge. / The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors : Long-term follow-up. In: Blood. 2009 ; Vol. 114, No. 20. pp. 4361-4368.
@article{71ffe50d8b5e468eb171ef3e2947cc73,
title = "The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up",
abstract = "Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP), and 13 in blast phase (BP). Best response to third TKI in CP was 5 major molecular responses (MMR), 3 complete cytogenetic (CCyR), 2 partial cytogenetic (PCyR), 3 minor cytogenetic (mCyR), 6 complete hematologic responses (CHR), and 6 with no response (NR). In AP, 1 patient achieved MMR, 1 CCyR, 2 PCyR, 1 mCyR, 4 CHR, and 1 NR. In BP, 1 achieved MMR, 2 CCyR, 1 PCyR, 1 mCyR, 2 returned to CP, and 6 NR. Median CCyR duration was 16.3 months; 3 CP patients achieving CCyR had a response more than 12 months. Median failure-free survival was 20 months for patients in CP, 5 months in AP, and 3 months in BP. Use of second-generation TKI after failure to 2 TKIs may induce responses, but these are usually not durable except in some CP patients. New treatment options are needed.",
author = "Garg, {Ravin J.} and Hagop Kantarjian and Susan O'Brien and Alfonso Quint{\'a}s-Cardama and Stefan Faderl and Zeev Estrov and Jorge Cortes",
year = "2009",
month = "11",
day = "12",
doi = "10.1182/blood-2009-05-221531",
language = "English (US)",
volume = "114",
pages = "4361--4368",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors

T2 - Long-term follow-up

AU - Garg, Ravin J.

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Quintás-Cardama, Alfonso

AU - Faderl, Stefan

AU - Estrov, Zeev

AU - Cortes, Jorge

PY - 2009/11/12

Y1 - 2009/11/12

N2 - Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP), and 13 in blast phase (BP). Best response to third TKI in CP was 5 major molecular responses (MMR), 3 complete cytogenetic (CCyR), 2 partial cytogenetic (PCyR), 3 minor cytogenetic (mCyR), 6 complete hematologic responses (CHR), and 6 with no response (NR). In AP, 1 patient achieved MMR, 1 CCyR, 2 PCyR, 1 mCyR, 4 CHR, and 1 NR. In BP, 1 achieved MMR, 2 CCyR, 1 PCyR, 1 mCyR, 2 returned to CP, and 6 NR. Median CCyR duration was 16.3 months; 3 CP patients achieving CCyR had a response more than 12 months. Median failure-free survival was 20 months for patients in CP, 5 months in AP, and 3 months in BP. Use of second-generation TKI after failure to 2 TKIs may induce responses, but these are usually not durable except in some CP patients. New treatment options are needed.

AB - Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP), and 13 in blast phase (BP). Best response to third TKI in CP was 5 major molecular responses (MMR), 3 complete cytogenetic (CCyR), 2 partial cytogenetic (PCyR), 3 minor cytogenetic (mCyR), 6 complete hematologic responses (CHR), and 6 with no response (NR). In AP, 1 patient achieved MMR, 1 CCyR, 2 PCyR, 1 mCyR, 4 CHR, and 1 NR. In BP, 1 achieved MMR, 2 CCyR, 1 PCyR, 1 mCyR, 2 returned to CP, and 6 NR. Median CCyR duration was 16.3 months; 3 CP patients achieving CCyR had a response more than 12 months. Median failure-free survival was 20 months for patients in CP, 5 months in AP, and 3 months in BP. Use of second-generation TKI after failure to 2 TKIs may induce responses, but these are usually not durable except in some CP patients. New treatment options are needed.

UR - http://www.scopus.com/inward/record.url?scp=73349100015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349100015&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-05-221531

DO - 10.1182/blood-2009-05-221531

M3 - Article

C2 - 19729517

AN - SCOPUS:73349100015

VL - 114

SP - 4361

EP - 4368

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -